Firstly, we used a 48-week finite course of PEG-IFN-α-2b because prolonged PEG-IFN-α-2b treatment might induce the incidence of AEs and lead to the acute decompensation in compensated liver cirrhosis. The gene discussed is IFNA1; the disease is cirrhosis of liver.